Shaobo Zhang, MD

Bio

CURRENT POSITION 

Associate Scientist, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

Visiting Professor, Capital University of Medical Sciences, Beijing, China 

EDUCATION 

M.D. Capital University of Medical Sciences, Beijing, China (1978-1983) 

M.S. Capital University of Medical Sciences, Beijing, China (1986-1989) 

Fellowship, Krebsliga Zyto Labor, St. Gallen, Switzerland (11/1991-5/1993) 

Fellowship, Department of Urology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota (9/1995-4/1999)

PROFESSIONAL TRAINING AND RESEARCH EXPERIENCES 

1983-1986: Resident, Department of Pathology, Capital University of Medical Sciences, Beijing, China. 

1986: Sino-Danish Post graduation Training Center. Advanced Cancer Diagnosis Training Program. Beijing China. 

1989-1991: Attending Pathologist, Department of Pathology, Friendship Hospital, Capital University of Medical Sciences, Beijing, China. 

1991-1993: Research Fellow, Klibersriga Zyto Labor, St. Gallen, Switzerland.

1993-1995: Attending Pathologist, Department of Pathology, Friendship Hospital, Capital University of Medical Sciences, Beijing, China. 

1995-1999: Research Fellow, Urology Research, Mayo Clinic, Rochester, Minnesota 1999-2002: Research Associate in Molecular Pathology, Indiana University School of Medicine, Indianapolis, IN. 

2002-2003: Assistant Scientist, Department of Pathology, Indiana University School of Medicine, Indianapolis, IN. 

2003-2004. Assistant Senior Biologist, Department of Endocrinology, Eli Lilly and Company, Indianapolis, IN. 

2005-present: Associate Scientist, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana.   

Key Publications

1. Cheng L, Zhang S, Wang L, MacLennan GT, Davidson DD. Fluorescence in situ hybridization in surgical pathology: principles and applications. J Pathol Clin Res. 2017;23;3:73-99.

2. Wang X, Lopez-Beltran A, Osunkoya AO, Wang M, Zhang S, Davidson DD, Emerson RE, Williamson SR, Tan PH, Kaimakliotis HZ, Baldridge LA, MacLennan GT, Montironi R, Cheng L. TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. Future Oncol. 2017;13:705-714.

3. Kouba E, Simper NB, Chen S, Williamson SR, Grignon DJ, Eble JN, MacLennan GT, Montironi R, Lopez-Beltran A, Osunkoya AO, Zhang S, Wang M, Wang L, Tran T, Emerson RE, Baldrige LA, Monn MF, Linos K, Cheng L. Solitary fibrous tumour of the genitourinary tract: a clinicopathological study of 11 cases and their association with the NAB2-STAT6 fusion gene. J Clin Pathol. 2017;70:508-514.

4. Emerson RE, Kao CS, Eble JN, Grignon DJ, Wang M, Zhang S, Wang X, Fan R, Masterson TA, Roth LM, Cheng L. Evidence of a dual histogenetic pathway of sacrococcygeal teratomas. Histopathol. 2017;70:290-300.

5. Sanfrancesco J, Eble J N, Grignon D J, Wang M, Zhang S, Sundaram C P, Idrees MT, Pili R, Kouba E, Cheng L. Genetic Heterogeneity in Clear Cell and Papillary Renal Cell Carcinomas with Sarcomatoid Features. Mol Carcinogenesis. in press

6. Liu Q, Cornejo K M, Cheng L, Hutchinson L, Wang M, Zhang S, Tomaszewicz K, Cosar E F, Woda B, Jiang Z. Next generation sequencing to detect deletion of RB1 and ERBB4 genes in chromophobe renal cell carcinoma: A potential role in distinguishing chromophobe renal cell carcinoma from renal oncocytoma. 2017; Mod Pathol in press.

7. Cheng L, Davidson DD, Wang M, Lopez-Beltran A, Montironi R, Wang L, Tan PH, MacLennan GT, Williamson SR, Zhang S. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. Histopathology. 2016;69:107-13.

8. Caliò A, Eble JN, Hes O, Martignoni G, Harari SE, Williamson SR, Brunelli M, Osunkoya AO, Wang L, Comperat E, Lopez-Beltran A, Wang M, Zhang S, Curless KL, Post KM, Chang HY, Luchini C, Baldrige LA, MacLennan GT, Montironi R, Grignon DJ, Cheng L. Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. Oncotarget. 2016

9. Cheng L, Davison DD, Adams J, Lopez-Beltran A, Wang L, Montironi R, Zhang S. Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol. 2014;89:73-111.

10. Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, Yang X, Knowles S, Horn W, Li Y, Zhang S, Yang Y, Vakili ST, Yu M, Burns D, Robertson K, Hutchins G, Parada LF, Clapp DW. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell. 2008;135:437-48.